Biggest News Aggregation in the World
📰 Durable Responses News

Page 3 - Durable Responses News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Durable Responses. Real-time updates on events, politics, business and more.

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia

Investegate announcements from NOVARTIS AG CHF0.50(REGD), FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia
United States East Hanover Novartis Scemblix Isabella Zinck Thomas Hungerbuehler Susanne Schaffert

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Novartis Pharma AG: FDA approves Novartis Scemblix (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia

Scemblix provides much-needed and long-awaited new option for patients with chronic myeloid leukemia (CML) who suffer with intolerance or inadequate response after at least two previous tyrosine
United States East Hanover Isabella Zinck Thomas Hungerbuehler Susanne Schaffert Floriana Riccio Furnari

Janssen Receives Positive CHMP Opinion for RYBREVANT (amivantamab) for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations After Failure of Platinum-Based Therapy

If approved by the European Commission, amivantamab will be the first treatment in the European Union specifically targeting EGFR exon 20 insertion mutations for advanced non-small cell lung cancer
United States United Kingdom Noah Reymond Jennifer Mcintyre Peter Lebowitz Catherine Taylor

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science